Cutaneous Myelofibrosis With JAK2 V617F Mutation: Metastasis, Not Merely Extramedullary Hematopoiesis!

被引:11
|
作者
Fraga, Garth R. [1 ]
Caughron, Samuel K. [2 ]
机构
[1] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA
[2] MAWD Pathol Grp, Kansas City, MO USA
关键词
myelofibrosis; extramedullary hematopoiesis; metastasis; JAK2; leukemia; MYELOID METAPLASIA; IDIOPATHIC MYELOFIBROSIS; SKIN; MANIFESTATION; PATHOGENESIS;
D O I
10.1097/DAD.0b013e3181d3ca2f
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm. There are 31 reported cases of cutaneous involvement by PMF, most of which have been described as "extramedullary hematopoiesis.'' We report a new case of cutaneous involvement by PMF and demonstrate mutation of the Janus kinase 2 gene in the cutaneous lesions. Extramedullary myelofibrosis is best considered a metastatic phenomenon. Reporting such cases as extramedullary hematopoiesis may cause confusion with reactive forms of extramedullary hematopoiesis.
引用
收藏
页码:727 / 730
页数:4
相关论文
共 50 条
  • [1] JAK2 (V617F) mutation in healthy individuals
    Passamonti, Francesco
    Rumi, Elisa
    Pietra, Daniela
    Lazzarino, Mario
    Cazzola, Mario
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 136 (04) : 678 - 679
  • [2] JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?
    Santos, Fabio P. S.
    Verstovsek, Srdan
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2012, 12 (09) : 1098 - 1109
  • [3] Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review
    Lussana, Federico
    Caberlon, Sabrina
    Pagani, Chiara
    Kamphuisen, Pieter W.
    Buller, Harry R.
    Cattaneo, Marco
    THROMBOSIS RESEARCH, 2009, 124 (04) : 409 - 417
  • [4] JAK2 V617F Mutation Prevalence in Myeloproliferative Neoplasms in Pernambuco, Brazil
    da Silva, Rafael Ramos
    Domingues Hatzlhofer, Betania Lucena
    de Faria Machado, Cintia Gonsalves
    de Melo Lima, Aleide Santos
    de Albuquerque, Dulcineia Martins
    Nunes dos Santos, Magnun Nueldo
    Fertrin, Kleber Yotsumoto
    Costa, Fernando Ferreira
    Araujo, Aderson da Silva
    Cavalcanti Bezerra, Marcos Andre
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2012, 16 (07) : 802 - 805
  • [5] Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders
    Basquiera, Ana L.
    Soria, Nestor W.
    Ryser, Ricardo
    Salguero, Miriam
    Moiraghi, Beatriz
    Sackmann, Federico
    Sturich, Ana G.
    Borello, Adriana
    Berretta, Adriana
    Bonafe, Miriam
    Moreno Barral, Jose
    Palazzo, Emilio D.
    Garcia, Juan J.
    HEMATOLOGY, 2009, 14 (06) : 323 - 330
  • [6] JAK2 V617F Mutation Status of 232 Patients Diagnosed With Chronic Myeloproliferative Neoplasms
    Payzin, Kadriye Bahriye
    Savasoglu, Kaan
    Alacacioglu, Inci
    Ozdemirkiran, Fusun
    Mutlu, Belgin Berber
    Bener, Sadi
    Calli, Aylin Orgen
    Kucukzeybek, Betul Bolat
    Aksun, Saliha
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (06) : 525 - 533
  • [7] Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells
    Cheng, Zhiyong
    Fu, Jianzhu
    Liu, Guimin
    Zhang, Lijun
    Xu, Qian
    Wang, Su-yun
    LEUKEMIA & LYMPHOMA, 2018, 59 (01) : 196 - 203
  • [8] Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
    Komrokji, Rami S.
    Seymour, John F.
    Roberts, Andrew W.
    Wadleigh, Martha
    To, L. Bik
    Scherber, Robyn
    Turba, Elyce
    Dorr, Andrew
    Zhu, Joy
    Wang, Lixia
    Granston, Tanya
    Campbell, Mary S.
    Mesa, Ruben A.
    BLOOD, 2015, 125 (17) : 2649 - 2655
  • [9] Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders
    Langabeer, S. E.
    Ainle, F. Ni
    Conneally, E.
    Lawler, M.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2007, 176 (02) : 105 - 109
  • [10] Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders
    S. E. Langabeer
    F. Ni Ainle
    E. Conneally
    M. Lawler
    Irish Journal of Medical Science, 2007, 176 : 105 - 109